3-(4-氯苯基)-N-(4-吡啶基甲基)金刚烷-1-甲酰胺

Opaganib

产品编号.: A385818 CAS号: 915385-81-8
分子式: C23H25ClN2O 分子量: 380.910404920578
纯度: 98% MDL NO.:

中文名称:3-(4-氯苯基)-N-(4-吡啶基甲基)金刚烷-1-甲酰胺
CAS号:915385-81-8
中文别名:3-(4-氯苯基)-N-(4-吡啶基甲基)金刚烷-1-甲酰胺
英文名称:Opaganib
英文别名:ABC294640;Opaganib;ABC 294640;Opaganib (ABC294640);3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;DRG21OQ517;Yeliva;GTPL6624;HMS3402P05;BCP08959;BDBM50393642;SB17167;DB12764;API0017247;S7174;Q27074100;(1s,3r,5R,7S)-3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxami;3-(4-Chlorophenyl)-N-(4-pyridinylmethyl)tricyclo[3.3.1.13,7]decane-1-carboxamide (ACI);ABC-294640;EX-A1962;EX-A1962;CS-0877;CS-0877;BRD-A70814879-001-01-2;BRD-A70814879-001-01-2;DTXSID801318727;DTXSID801318727;ABC294640Opaganib?;ABC294640Opaganib?;HY-16015;HY-16015;BRD-A70814879-003-01-8;BRD-A70814879-003-01-8;(1s,3r,5R,7S)-3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;(1s,3r,5R,7S)-3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;BRD-A70814879-003-02-6;BRD-A70814879-003-02-6;NSC796101;NSC796101;AKOS027327311;AKOS027327311;4-PYRIDINYLMETHYL 3(4-CHLOROPHENYL)ADAMANTINE CARBOXAMIDE;4-PYRIDINYLMETHYL 3(4-CHLOROPHENYL)ADAMANTINE CARBOXAMIDE;AC-33116;AC-33116;CHEMBL2158685;CHEMBL2158685;CCG-268417;CCG-268417;NSC-796101;NSC-796101;AS-56117;AS-56117;OPAGANIB [WHO-DD];OPAGANIB [WHO-DD];BA162479;BA162479;SCHEMBL1548333;SCHEMBL1548333;915385-81-8;915385-81-8;CHEBI:124965;CHEBI:124965;OPAGANIB [INN];OPAGANIB [INN]
EINEC:
分子式:C23H25CLN2O
分子量:380.910404920578
搜索质检报告(COA)
搜索MSDS
已经到最底了
批量搜索 关闭
批处理可以通过CAS号,CAS号,每行一个搜索
...

3-(4-氯苯基)-N-(4-吡啶基甲基)金刚烷-1-甲酰胺
ABC294640;Opaganib;ABC 294640;Opaganib (ABC294640);3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;DRG21OQ517;Yeliva;GTPL6624;HMS3402P05;BCP08959;BDBM50393642;SB17167;DB12764;API0017247;S7174;Q27074100;(1s,3r,5R,7S)-3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxami;3-(4-Chlorophenyl)-N-(4-pyridinylmethyl)tricyclo[3.3.1.13,7]decane-1-carboxamide (ACI);ABC-294640;EX-A1962;EX-A1962;CS-0877;CS-0877;BRD-A70814879-001-01-2;BRD-A70814879-001-01-2;DTXSID801318727;DTXSID801318727;ABC294640Opaganib?;ABC294640Opaganib?;HY-16015;HY-16015;BRD-A70814879-003-01-8;BRD-A70814879-003-01-8;(1s,3r,5R,7S)-3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;(1s,3r,5R,7S)-3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;BRD-A70814879-003-02-6;BRD-A70814879-003-02-6;NSC796101;NSC796101;AKOS027327311;AKOS027327311;4-PYRIDINYLMETHYL 3(4-CHLOROPHENYL)ADAMANTINE CARBOXAMIDE;4-PYRIDINYLMETHYL 3(4-CHLOROPHENYL)ADAMANTINE CARBOXAMIDE;AC-33116;AC-33116;CHEMBL2158685;CHEMBL2158685;CCG-268417;CCG-268417;NSC-796101;NSC-796101;AS-56117;AS-56117;OPAGANIB [WHO-DD];OPAGANIB [WHO-DD];BA162479;BA162479;SCHEMBL1548333;SCHEMBL1548333;915385-81-8;915385-81-8;CHEBI:124965;CHEBI:124965;OPAGANIB [INN];OPAGANIB [INN]